News

Filterlex Medical Announces Positive Results from A First-In-Human Study for the CAPTIS® Full-Body Embolic Protection Device

Cardiovascular data presented at EuroPCR 2022 demonstrates successful device performance during a TAVR procedure with no complications.  Caesarea, Israel, May 31st, 2022 – Filterlex Medical Ltd., a cardiovascular medical device startup, announced today results from a first-in-human (FIH) study demonstrating the safety, feasibility, and performance of the CAPTIS device. CAPTIS is a next-generation, full-body embolic …

Filterlex Medical Announces Positive Results from A First-In-Human Study for the CAPTIS® Full-Body Embolic Protection Device Read More »

Filterlex Medical Successfully Completes First-In-Human Study for CAPTIS® Full-Body Embolic Protection Device

Cardiovascular study results to be presented by Prof. Ran Kornowski, Director of the Cardiology Center, Rabin Medical Center at the EuroPCR 2022 conference in May Caesarea, Israel, May 10th, 2022 – Filterlex Medical Ltd., a cardiovascular medical device startup, announced today that it has completed its CAPTIS First-In-Human (FIH) study. Study results will be presented …

Filterlex Medical Successfully Completes First-In-Human Study for CAPTIS® Full-Body Embolic Protection Device Read More »

Cardiovascular Startup, Filterlex Medical, Selected to Receive €7M from the European Innovation Council

Equity investment to support advancement of its breakthrough full-body embolic protection device to reduce the risk of stroke and other complications during left-heart procedures. Caesarea, Israel, Dec 21st, 2021– Filterlex Medical, a cardiovascular medical device startup, announced today that it has been selected to receive €7 Million equity investment from the European Innovation Council Accelerator (EIC).  The …

Cardiovascular Startup, Filterlex Medical, Selected to Receive €7M from the European Innovation Council Read More »

Filterlex Medical Closes a $6Million Series A1 Investment to Accelerate the CAPTIS® Cardiovascular Clinical Program

Caesarea, Israel, Nov 18th, 2021– Filterlex Medical, a cardiovascular medical device startup, announced today that it has recently completed a US $6 Million series A1 investment round from leading private healthcare investors. The financing will accelerate implementation of the company’s CAPTIS® clinical program. The CAPTIS is a next-generation, full-body embolic protection device to reduce the …

Filterlex Medical Closes a $6Million Series A1 Investment to Accelerate the CAPTIS® Cardiovascular Clinical Program Read More »

The European Commission Horizon 2020 Program Backs Filterlex’s Embolic Protection Device – CAPTIS

€2.1M Grant to support Filterlex’s CAPTIS clinical trials Yokneam, Israel (September 16, 2019) – Filterlex Medical, an innovative medical device startup in the cardiovascular field,  today announced that the company has been selected for the Phase 2 Horizon 2020 SME Instrument program. The SME Instrument program awards financial support to companies that demonstrate world class …

The European Commission Horizon 2020 Program Backs Filterlex’s Embolic Protection Device – CAPTIS Read More »